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Background: Magnetic resonance imaging (MRI) acquisition/processing techniques assess brain 
volumes to explore neurodegeneration in Alzheimer’s disease (AD).  
Objective: We examined the clinical utility of MSmetrix and investigated if automated MRI volumes 
could accurately discriminate between groups covering the entire AD continuum and could be used as 
a possible predictor for clinical progression. 
Methods: The Belgian Dementia Council initiated a retrospective, multi-center study and analyzed 
whole brain (WB), grey matter (GM), white matter (WM), cerebrospinal fluid (CSF), cortical GM (CGM) 
volumes, and WM hyperintensities (WMH) using MSmetrix in an AD population. Baseline (n=887) and 
follow-up (FU, n=95) T1-weighted brain MRIs and time-linked neuropsychological data were available.  
Results: The cohort consisted of cognitively healthy controls (HC, n=93), subjective cognitive decline 
(SCD, n=102), mild cognitive impairment (MCI, n=379), and AD dementia (n=313). Baseline WB and GM 
volumes could accurately discriminate between clinical diagnostic groups and were significantly 
decreased with increasing cognitive impairment. MCI patients had a significantly larger change in WB, 
GM, and CGM volumes based on two MRIs (n=95) compared to HC (FU >24months, p=0.020).  
Single variable linear regression models showed that baseline atrophy of WB, GM, CGM, and increased 
CSF volumes predicted cognitive impairment. Moreover, the prediction of cognitive impairment based 
on decline in MMSE score divided by the follow-up time was also correlated with WB, GM, and CGM. 
Conclusion: WB and GM volumes extracted by MSmetrix could be used to define the clinical spectrum 
of AD accurately and along with CGM, they are able to predict cognitive impairment based on (decline 
in) MMSE scores. Therefore, MSmetrix can support clinicians in their diagnostic decisions, is able to 






In Alzheimer’s disease (AD), the spread of neurodegeneration, and especially tau pathology and 
synapse loss, is the most important pathological substrate of clinical symptoms [1]. Biomarkers of 
neurodegeneration, including volumetric analyses of relevant brain regions on magnetic resonance 
imaging (MRI), correlate better with the degree of cognitive impairment in AD patients as compared 
to biomarkers of amyloid-β (Aβ) deposition [1-3]. Volumetric brain imaging should include areas in 
which the neuropathological process of AD is prominent, such as the medial temporal lobe (MTL) that 
includes the hippocampus. The atrophy can often be detected at the stage of mild cognitive 
impairment (MCI) [4-15]. Therefore, hippocampal volume has been proposed as a neuroimaging 
biomarker for early AD diagnosis in the revised diagnostic criteria of AD [16-20]. Other neuro-
anatomical structures, such as the entorhinal cortex [7, 9, 21, 22] and cerebral cortex [23] are also 
prone to AD pathology. Their morphological characteristics such as volume, shape, and thickness can 
be used as biomarkers of the extent of neurodegeneration as well [24, 25]. Nevertheless, measuring 
brain atrophy has some limitations because evolution of disease-related regional atrophy does not 
necessarily follow the anatomical boundaries of structures. To overcome these limitations, the whole 
brain (WB) and the (whole) grey matter (GM) volumes have been used as neuroimaging biomarkers 
for AD diagnosis and evolution [3, 26-33]. Since these anatomical structures are considerably larger 
than the hippocampus or cortex, the automated quantification of their volumes is, in general, less 
prone to measurement errors.  
To date, different MRI acquisition and processing techniques have been developed to measure 
volumes of specific brain regions. However, their accuracy is still limited by a moderate sensitivity and 
a rather low specificity for AD [34]. Manual segmentation approaches, which are time consuming, have 
been widely used and are considered a standard approach by experts in neuroanatomy [35, 36], 
though large-scale studies are limited [4, 37]. Semi-automated techniques are less time consuming, 
however a priori information such as user-defined landmarks is needed, which also limits their 
usefulness for large clinical studies [38-40]. To date, an increasing number of studies have investigated 
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structural brain changes in AD populations with an automated image-based brain morphometry 
analysis, as this is less time consuming and does not suffer from large intra- and inter-observer 
variability compared to manual and semi-automated approaches. This trend relates to both the 
widespread availability of brain imaging equipment in clinical routine and research, and the concurrent 
development of image analysis software packages released over the past years [41-46]. MSmetrix, is 
another fully automated and European Conformity (CE)-labelled and Food and Drug Administration 
(FDA)-cleared tool, specifically designed to measure atrophy in patients with multiple sclerosis (MS) 
and has been validated in these patients (we refer to Supplemental data for more detailed information 
of the validation process) [47-51]. As this method uses clinical brain MRI scans in contrast to many 
other tools that apply MRI scans from selected clinical trial/research cohorts, we decided to use the 
output of MSmetrix, which included WB, (whole) GM, white matter (WM), cerebrospinal fluid (CSF), 
cortical GM (CGM) volumes, and WM hyperintensities (WMH), in a ‘retrospective Belgian multi-center 
MRI biomarker study in dementia’ (REMEMBER). We examined whether MSmetrix is an accurate and 
reproducible segmentation approach to differentiate between healthy controls and AD patients, 
covering the entire AD continuum, and thus is of clinical utility for the diagnostic work-up and for 
clinical trials. Therefore, we set up a study to assess the diagnostic value of automated volumetry using 
MSmetrix in a population comprising the entire AD continuum (AD, MCI, subjective cognitive decline 
(SCD)), as well as cognitively healthy elderly (primary objective). The secondary objective of this study 
was to investigate if automated volumetry using MSmetrix is an early diagnostic marker for AD and as 
a possible predictor for clinical progression.  
 
Materials and Methods 
Study design  
The retrospective Belgian multi-center study cohort consists of participants who underwent a baseline 
brain MRI scan, in combination with a clinical neurological and neuropsychological evaluation for 
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diagnostic purposes. A neuropsychological evaluation, at least consisting of a screening instrument 
such as the Mini-Mental State Examination (MMSE) test was sufficient to be included in the study.  
A subset of the population underwent a repeat brain MRI scan with or without a neuropsychological 
evaluation (time interval between baseline and follow-up investigations, for both MRI and 
neuropsychological evaluations, was at least three months). 
The study was approved by the ethics committee of University of Antwerp / Universitair Ziekenhuis 
Antwerpen (N°16/2/18), Antwerp and by the ethics committees of Algemeen Ziekenhuis Sint-Jan 
Brugge-Oostende, Brugge (N°1992); Centre Hospitalier Universitaire Brugmann (CHU Brugmann), 
Brussels (N°2016/84); Centre Hospitalier Universitaire Liège (CHU Liège), Liège (N°2012/274); Cliniques 
Universitaires de Bruxelles (ULB), Hôpital Erasme, Brussels (N°P2016/187); Cliniques Universitaires 
Saint-Luc (UCL), Brussels (N°2016/07jui/261); Cliniques St-Pierre Ottignies, Ottignies (N°OM045); 




Patients and cognitively healthy controls were selected from existing cohorts in several memory clinics 
that are members of the Belgian Dementia Council (BeDeCo). SCD, MCI, and dementia due to AD 
patients were included in this retrospective multi-center study. The group of cognitively healthy elderly 
was selected amongst available (research) cohorts, like spouses of patients who visited the memory 
clinic and community-dwelling volunteers. 
 
Clinical diagnostic criteria 
In order to avoid a selection bias, all patients were considered for inclusion, irrespective of the severity 
of cognitive deterioration. The patients were diagnosed by an experienced clinician in each center. 
Diagnosis of dementia due to AD was based on NIA-AA criteria [17, 19]. At baseline, MCI due to AD 
was diagnosed by applying the NIA-AA criteria [16-18, 20]. When sufficient neuropsychological data 
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were available, MCI patients were divided into four subgroups. MCI patients were categorized in 
single-domain (sd) and multi-domain (md) MCI based on the neurocognitive domains scoring below 
1.5 SD on their respective z-scores. Z-scores were used from population-based norms and were age-
adjusted. In addition, MCI patients were also categorized as amnestic MCI (aMCI) and non-amnestic 
MCI (naMCI) based on z-scores below -1.5 SD per cognitive domain. In case the delayed memory 
domain was below a z-score of 1.5 SD, a patient was classified as aMCI, whereas naMCI was based on 
z-scores from one of the other cognitive domains, such as immediate memory, 
visuospatial/constructional abilities, language or attention. SCD patients were diagnosed by the 
Jessen’s et al. criteria in the same way as the MCI patients but without an objective cognitive 
impairment, so all neuropsychological subtests having a z-score above -1.5 [52]. All control subjects 
underwent at least a cognitive screening test to rule out cognitive impairment. The control subjects 
did not meet the Jessen’s et al. criteria of SCD [52].  
Exclusion criteria for the total population consisted of brain tumors, large cerebral infarction/bleeding, 
strategic infarctions, other neurodegenerative diseases, severe head trauma, epilepsy, brain 
infections, severe depression, unregulated diabetes mellitus, untreated thyroid disorders, or any 




All MRI scans were obtained from respective Neuroimaging Departments, to which subjects were 
referred. MRI scans from all scanner types were accepted. The minimal requirements for the MRI 
protocol included a T1-weighted image with a preferred voxel size of the 3D T1 (1x1x1mm). A FLAIR 
image was optional, with the same preferences as the above described T1-weighted image.  
 
Image analyses  
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The MRI data were processed using the CE-labelled and FDA-cleared software called MSmetrix, to 
extract WB, GM, WM, CSF (intra- and inter-ventricular CSF), CGM, and WMH volumes (MSmetrix-
cross). Thereto, the T1-weighted MRI images were segmented into WM, GM, and CSF using a 
probabilistic model, including bias field correction. In case a FLAIR image was available, WMH were 
extracted using an outlier model and lesion filling of the T1-weighted image was performed prior to 
segmentation into WM, GM, and CSF [50]. Finally, WB was computed as WM and GM, while CGM was 
extracted from the GM segmentation based on prior knowledge of the shape and appearance of the 
cortical area. The duration was approximately less than 30 minutes per individual. This includes on 
average 22 minutes processing and 7 minutes QC per subject. 
If a repeat brain MRI was available a longitudinal registration based approach was used, using the 
cross-sectional segmentations as an input to extract brain atrophy and lesion changes (MSmetrix-long). 
This ensures a low measurement error of the brain atrophy measurements [47] and a more consistent 
evaluation of lesion changes [49].  
All extracted measures were corrected for head size, as a consequence only normalized measures were 
used in further analyses. Head size was normalized by scaling the measured volume of the image with 
the determinant of the affine transformation matrix that describes the transformation between the 
Montreal Neurological Institute (MNI) atlas and the image. 
A quality control (QC) of the extracted measurements was performed per center by E.N. and H.S.. 
Moreover, a visual assessment of the segmentations was performed for all ‘outlier’ measurements. 
The ‘outliers’ included scans with volumes below the 10th and above the 90th percentile within the 
cohort of the center. Volumes that were not correctly segmented were completely rejected or 
approved with remarks. In detail, in case the segmentation approach completely failed, volumes were 
not trustworthy and values were excluded for further analyses. If the volumetric approach was in part 
correctly segmented and the WB volumetric analysis could be trusted, the scans were classified as 
approved with remarks. All other scans, with a correct segmentation were subdivided as approved. 
WMH underwent the same ‘outlier QC’ and were divided into two groups, namely approved or 
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rejected. The QC of the scans was always dependent on the protocol used in each center. Therefore, 
scans were often rejected due to a low quality of the scans and/or large slice thickness (>3mm) that 
led to missegmentation of the volumes. 
 
Statistical analyses 
Distribution of categorical variables, such as gender, within subject groups were analyzed with a Chi-
Square test, and percentages were reported. Demographic comparisons and other analyses including 
MRI measures were based on ANOVA and/or ANCOVA tests with post hoc Bonferroni tests. ANCOVA 
tests were performed to analyze the extracted MRI measures and were corrected for center and age 
at baseline (date of MRI acquisition) in cross-sectional analyses. Longitudinal analyses, performed by 
ANCOVA tests to analyze the differences in volumes between two MRI scans were corrected for center, 
age at baseline, and time between the MRI scans. In case neuropsychological test scores were used as 
outcome variable, ANCOVA tests corrected for years of education, age at baseline, and baseline clinical 
diagnoses were used (based on baseline MRI scans). Field strength was not included as a covariate, as 
the study of Lysandropoulos et al. detected no significant difference for this variable when MSmetrix 
was used [48]. Area under the curves (AUCs) of receiver operating characteristics (ROC) curves were 
calculated for volumetric measurements and cut-offs were determined. A single variable linear 
regression model was used to analyze the relationship between volumetric measures and the MMSE 
scores. In the first model, the relationship of each volume (independent variable) with MMSE score 
(dependent variable) was assessed (model 1). In a second model, the same relationships were assessed 
after controlling for age and baseline clinical diagnosis (model 2). Results are represented as 
standardized regression coefficients (β-values) with 95% CI and p-values to allow comparisons of effect 
sizes. 
For all analyses, two-tailed p-values below 0.05 were considered significant. All statistical analyses 





Overview of the REMEMBER cohort 
The study cohort from eight Belgian centers, included cognitively healthy controls (n=93), SCD (n=102), 
MCI (n=379), and AD dementia patients (n=313), and represented a total of 887 subjects 
(Supplemental Table 1).  
Baseline brain MRI scans were available for all subjects and volumetric analyses were performed 
(MSmetrix-cross). Baseline scans were acquired at 1.5T (Siemens, n=126; GE, n=90; Philips, n=119) and 
3T scanners (Siemens, n=313; GE, n=50; Philips, n=189; we refer to Supplemental Table 2 and 3 for 
more detailed information). In total, 746 scans (84%) were approved after QC and all volumes (WB, 
GM, WM, CSF, CGM) were included for further analyses. Fifty-eight MRI scans were approved with 
remarks after QC as the volumes were not correctly segmented but WB volumes were still accurate 
and were included in the analyses of WB volume. This led to a total of 804 subjects (91%) with an 
approved WB volume. Eighty-three scans were excluded for analysis due to large slice thickness 
(>3mm) and/or missegmentation of volumes due to low quality of scans. To analyze WMH, 629 FLAIR 
sequences were available of which 170 scans were rejected after QC, and further analysis was 
performed on a total of 459 MRI scans (73%).  
Follow-up brain MRI scans were available in 95 subjects (11%) and all volumetric analyses were 
approved, for both MSmetrix-cross and MSmetrix-long. Follow-up scans were acquired at 
1.5T(Siemens, n=4; Philips, n=7) and 3T scanners (Siemens, n=75; ] Philips, n=9). The cohort consisted, 
based on baseline diagnosis, of a group of cognitively healthy controls and SCD, abbreviated as HC-SCD 
(n=25), MCI (n=50), and AD dementia patients (n=20).  
 
Study population 
The demographic and clinical characteristics of the different diagnostic subgroups are given in Table 1. 
The AD dementia group consisted of significantly more females than males. Age at baseline was 
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significantly different between all groups (p=0.001), except between cognitively healthy controls and 
SCD patients. AD dementia patients were the oldest patient group followed by MCI, SCD, and controls. 
Time between baseline MRI and neuropsychological examination was in most cases short (mean 
[interquartile range (IQR)] 2.7 [0.0-2.1] months). In total, 633 subjects were clinically followed-up with 
a mean total follow-up of 2.1 [IQR: 0.6-3.2] years (Table 1). The time interval between baseline MRI 
scan and last clinical visit was only significantly different between MCI and AD dementia patients, 
which was shorter for AD dementia patients compared to the MCI group. In case an SCD subject 
developed MCI/AD dementia (n=15/n=2, 17%) or in case an MCI patient progressed to dementia 
(n=101, 27%), the time between baseline MRI and diagnostic conversion was not different between 
those two groups (mean [IQR] 1.8 [0.9-2.4] years, p=0.066). MMSE scores were significantly different 
between all groups, except between cognitively healthy controls and SCD patients, with the lowest 
scores in AD dementia patients and highest scores in the control and SCD subjects. Cognitively healthy 
controls and SCD patients were significantly more educated than MCI and AD dementia patients. 
In total, 95 subjects had a follow-up MRI scan (Table 2). Gender, time between scans, and time 
between baseline and last clinical follow-up/conversion were not significantly different between the 
clinical diagnostic groups. The MCI and AD dementia patients were significantly older compared to the 
HC-SCD subjects (respectively, p=0.006 and p=0.009). MMSE scores were significantly different 
between all clinical diagnostic groups (p=0.001). Individuals with a follow-up MRI scan had higher 
MMSE scores compared to subjects without a follow-up scan, however this was only significantly 
different in the MCI patients (p=0.004). HC-SCD subjects were higher educated compared to AD 
dementia subjects (p=0.018). 
 
Imaging analyses 
Cross-sectional MSmetrix analyses in the total population  
All volumes and WMH discriminated AD dementia patients and cognitively healthy controls with a high 
diagnostic accuracy (sensitivity and specificity), as shown in Table 3 (for cut-offs, see Supplemental 
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Table 4). Cross-sectional analyses, corrected for age at baseline and center, showed significant 
differences between all clinical diagnostic groups for WB (Fig. 1A). GM was significantly different 
between all groups, except between cognitively healthy controls and SCD patients (Fig. 1B). WM and 
CSF volumes were significantly different between controls and all other groups, and CSF volumes of 
AD dementia patients were significantly larger than SCD and MCI patients. MCI and AD dementia 
patients showed a significant smaller CGM volume compared to controls and SCD (Fig. 1C). The largest 
WB, GM, WM, and CGM volumes were detected in the control group and decreased by cognitive 
impairment (SCD<MCI<AD dementia), whereas the opposite was found for the CSF volume. No 
significant differences were detected for the WMH between the different clinical diagnostic groups. 
Stable MCI patients (n=162) and MCI patients that progressed to AD dementia (n=101) were not 
significantly different for any of the volumetric measurements and WMH on baseline MRI scans. 
 
Cross-sectional MSmetrix analyses in the MCI patients 
By dividing the MCI patients in sd MCI (n=129) and md MCI (n=211), significantly larger volumetric 
measurements were detected between HC and all other diagnostic groups, SCD and md MCI patients 
or AD dementia, and sd MCI and AD dementia patients. In case aMCI and naMCI were taken into 
account, both sd MCI subgroups (sd aMCI, n=84; sd naMCI, n=45) had significantly larger volumes (all 
volumetric measurements) compared to AD dementia, whereas no significant differences were 
detected between both md MCI groups (md aMCI (n=191) and md naMCI (n=20)) and AD dementia. In 
addition, the only MCI subgroup that had significantly smaller volumes (all volumetric measurements) 
compared to SCD was the md aMCI group. WMH were not significantly different between any MCI 
patient subgroup. 
 
Longitudinal MSmetrix analyses (Table 2) 
Longitudinal data analyses (n=95), of two MRI scans for the same subject, corrected for center, age at 
baseline MRI scan, and time between MRI scans showed no significant differences between clinical 
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diagnostic groups for the change in volumes over time. However, in case the interval between two 
scans was more than 24 months (n=31) there was a significant difference between the HC-SCD (n=10) 
and MCI (n=16) patients for the change in WB (mean difference of 2.130, p=0.019), GM (mean 
difference of 2.524, p=0.038), and CGM (mean difference of 2.475, p=0.048). The largest changes were 
detected in the AD dementia group and the smallest changes in the HC-SCD for WM, GM, and CGM.  
 
Neuropsychological data analyses in combination with volumetric MRI measures 
An MMSE score was available for 93% of all subjects. Linear regression models per volume (model 1), 
significantly predicted the MMSE scores for all volumes (Table 4). When age and clinical diagnosis at 
baseline were introduced to the analyses (model 2), WB, GM, CSF, and CGM could significantly predict 
MMSE score.  
Follow-up MMSE scores, with at least three months between baseline and last follow-up MMSE score, 
were available in 429 subjects (2.4 [1.1-3.4] years). The MMSE slopes were calculated based on the 
difference in MMSE scores and were divided by the follow-up time. Subjects were divided in four 
groups: (1) subjects with an improvement in MMSE score (n=117, improvers: MMSE slope< 0), (2) with 
no change in MMSE score (n=71, stable: MMSE slope=0), (3) with a slow decline (n=182, slow 
decliners), and (4) with a fast decline in MMSE score (n=59, fast decliners). Subjects were categorized 
as slow decliners in case the MMSE slope was smaller than three, and if the slope was equal or larger 
than three subjects were categorized as fast decliners. Significant differences were found for the 
baseline measurements of WB, GM, and CGM between fast and slow decliners, with smaller baseline 
volumes in the fast decliners (Fig. 2). 
 
Discussion 
In the present large multi-center study, including 887 subjects, we analyzed volumetric brain 
measurements with the CE-labeled and FDA-approved software pipeline MSmetrix that has been 
developed for clinical use in MS and has proven high accuracy for longitudinal analyses at the individual 
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patient level [47-51]. Moreover, this study used this fully automated segmentation approach to further 
decrease the observer dependency as well as the time needed from the expert (<30min/subject), and 
standardize the quantification of MRI readings. Thus, the fully automated procedure has reduced 
reliance on anatomical expertise and provide rapid results compatible with clinical practice. In 
addition, MSmetrix uses clinical brain MRI scans in contrast to many other tools that apply MRI scans 
from selected clinical trial/research cohorts. Another advance of MSmetrix is the use of Digital Imaging 
and Communications in Medicine (DICOM) format images, which are ideal to create a fast clinical 
workflow. Therefore, MSmetrix translates the volumetric measures from a research setting to routine 
clinical practice. Nevertheless, in differential dementia diagnosis the usefulness of these MRI measures 
is limited due to effect that atrophy is not AD-specific. 
By applying this software in the AD continuum and cognitively healthy elderly, we found that the 
volumetric volumes were significantly smaller with increased cognitive impairment. In addition, WB 
and GM accurately discriminated between clinical diagnostic groups, whereas WM, CSF, and CGM 
were less accurate. For this reason, the output measures of MSmetrix are able to support the clinical 
diagnostic work-up of AD. The diagnostic accuracies of the volumetric measures are comparable or 
better compared to the current literature [3, 26, 53-55]. WMH were not significantly different between 
diagnostic groups. A higher degree of WMH is known to be associated with poorer cognitive function 
[56, 57]. However, the lack of significant differences could be explained by the reflection of low 
variability, as a trend was found in the expected direction with more WMH by more cognitive 
impairment (Table 1). 
In addition, the method failed to distinguish stable MCI patients from MCI patients that progressed to 
AD dementia as no significant differences were detected for baseline volumetric measurements. A 
possible explanation is that volume change of specific brain regions over time may be more indicative 
than a static cross-sectional assessment. Moreover, the brain is affected by normal aging and disease 
progression, and there is individual variation in brain anatomy, which makes it difficult to discriminate 
between groups. Especially the MCI subgroups are difficult to distinguish as they are in the same 
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disease stage of the continuum. Longitudinal data could avoid the limitations of cross-sectional 
analyses [58-61], however in our cohort also no differences between the stable MCI patients and MCI 
converters were detected in the longitudinal analyses. Probably, this is due to a small sample size of 
available longitudinal MRI scans in MCI patients (n=50, of which 9 converters). In general, brain volume 
changes over time correlate with and predict deterioration of cognitive performance [34] and seem 
more sensitive to AD-like brain atrophy features than CSF measures or β-amyloid deposition measured 
with positron emission imaging (PET) [62]. Thus, longitudinal assessment of MSmetrix-long is relevant 
in the setting of chronic and progressive neurologic conditions, such as AD and MS. Another solution 
to differentiate the MCI subgroups is to consider analyzing specific brain regions, such as the 
hippocampus [13-15]. Nevertheless, our longitudinal data analyses (interval between MRI scans >24 
months) showed a significant decrease in WB, GM, and CGM volumes in MCI patients compared to the 
HC-SCD patients. As the sample size of longitudinal data was small we should interpret the results with 
caution. However, these results are in line with ADNI data, however in those studies a significant 
difference after 12 months interval was also detected [63, 64]. 
The primary objective of this study was to identify which atrophy measures accurately discriminate 
between groups by using MSmetrix. Our cross-sectional data confirm that a high diagnostic accuracy 
was observed between AD dementia patients and cognitively healthy controls for the extracted 
volumes. However, when corrected for age and center, WB and GM were the most robust MRI 
biomarkers to distinguish between clinical groups. Those volumetric measures can support disease 
diagnosis and thus, may assist clinicians in their decisions. The secondary objective was to investigate 
MSmetrix as a possible predictor for clinical progression. The single variable linear regression models 
showed that increased CSF volumes and atrophy of WB, GM, and CGM predicted cognitive impairment, 
independent of age and baseline diagnosis, which is confirmed by other studies [65-67]. Next, the 
prediction of disease evolution based on the decline in MMSE score was also detected in WB, GM, and 
CGM where slow and fast MMSE decliners showed significant differences for those volumes, with 
smaller baseline volumes in the fast decliners, in line with the literature [3, 30-32]. In here, the 
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volumetric measures are of help to the clinicians to track the clinical progression of the disease, as 
increased CSF volumes and brain atrophy correlate with clinical decline. 
This study focused on the output measurements of MSmetrix, which are large volumes (WB, GM, WM, 
CSF, CGM) that can overcome the limitations of disease-related regional atrophy. Nevertheless, many 
groups investigated regional atrophy and especially MTL, including hippocampal atrophy, as this is a 
sensitive AD biomarker [18, 34]. A potential benefit of these specific AD-pathological regions is that 
they possibly allow the discrimination between sd MCI and md MCI patients [13-15, 55]. This possible 
discrimination was not observed in the current study, as expected by the proposed models [18, 20]. 
Indeed, sd MCI patients and SCD subjects had comparable volumes and also no significant difference 
was found between md MCI and AD dementia patients. A possible explanation could be that the 
neuropsychological examinations showed inter- and intra-rater and/or center variability as the 
neuropsychological tests were administered in different centers by different neuropsychologists. To 
take this limitation into account a correction for center was applied in the statistical analyses. 
Another limitation of this study was the significant difference in age for diagnostic groups at baseline, 
although we corrected the statistical analyses to overcome this problem. Next, few follow-up MRI 
scans were available which probably led to less significant differences in the longitudinal volumetric 
measurements. Lastly, analyzing the different volumes based on only T1 images versus T1 in 
combination with FLAIR sequences could be seen as another limitation of this study, as differences in 
results could be found in case larger WMH volumes were present. Those WMH volumes could be 
wrongly detected as GM volumes. Nevertheless, the WB volume is usually robust because WMH 
volumes are classified as CSF, as has been observed in the validation of MSmetrix in MS patients [47-
51]. Despite these disadvantages, the large amount of data included in this multi-center study, the 
short time between baseline measures, and the mean clinical follow-up time of 2.1 years [IQR: 0.6-3.2] 
are certainly strengths of this study. Even though we have used MRI scans that were acquired in routine 
clinical practice, and thus from different scanner types which could be seen as a limitation, only 15.9% 
of the scans were rejected, which demonstrates the clinical usefulness of this method. Moreover, 
18 
 
MSmetrix can be integrated easily in the clinical workflow as it uses DICOM images from all scanner 
types without any restrictions of the image sequences and produces results in an accurate and rapid 
way.  
In conclusion, volumes measured with a fully automated tool (MSmetrix) accurately discriminated 
between clinical diagnostic groups in an AD population, and thus can support clinicians in their 
decisions. Especially WB and GM, and CGM are MRI biomarkers that distinguished between clinical 
diagnostic groups and were possible predictors for clinical progression based on (decline in) MMSE 
scores. Those volumes could therefore be used to define the clinical spectrum of AD more accurately, 
are able to track clinical progression of disease, are of help to select appropriate populations for clinical 
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Tables and Figures 
Table 1 REMEMBER baseline study population 
 Controls (n=93) SCD (n=102) MCI (n=379) AD dementia (n=313) p-value 
Gender (%male/female) 47/53 46/54 51/49 39/61 0.018 









Time between BL NPE 











Time between BL and 
conversion (years) (n) 


























































































Legend: data are mean±SD and [IQR], percentages (%), and numbers (n). P-values are general Chi-Square for gender or 
ANCOVA test results (for all other measures), whereas the p-values described below are based on the differences of post hoc 
analyses. Normalized brain volumes (WB, GM, WM, CSF, CGM, and WMH) are reported. 
¶ SCD vs. MCI p=0.013. Other comparisons: p=0.001. ¥ SCD vs. MCI p=0.003; MCI vs. AD dementia p=0.043. Other comparisons: 
p=0.001. £ Controls vs. SCD p=0.018. Other comparisons: p=0.001. ± Controls vs. SCD p=0.008; MCI vs. AD dementia p=0.007. 
Other comparisons: p=0.001. § SCD vs. MCI p=0.004. Other comparisons: p=0.001. 
* Significantly different compared to SCD. ^ Significantly different compared to MCI. # Significantly different compared to AD 
dementia. ‡ Significantly different compared to controls. 
Abbreviations: AD Alzheimer’s disease; BL baseline; CGM cortical grey matter; CSF cerebrospinal fluid; FU follow-up; GM grey 
matter; IQR interquartile range; MCI mild cognitive impairment; MMSE Mini-Mental State Examination; NPE 
neuropsychological examination; REMEMBER retrospective Belgian multi-center MRI biomarker study in dementia; SCD 
subjective cognitive decline; SD standard deviation; WB whole brain; WM white matter; WMH white matter hyperintensities; 




Table 2 REMEMBER based on follow-up MRI: study population 
 HC-SCD (n=25) MCI (n=50) AD dementia (n=20) p-value 
Gender (%male/female) 40/60 46/54 55/45 NS 
Age at BL (years) 66.0 [60.2-70.6] ^,# 72.2 [67.8-77.3] ‡ 72.9 [67.7-78.7] ‡ 0.006, 0.009¶ 
Time between scans (months) 23.5 [12.5-27.0] 20.9 [12.4-24.7] 17.9 [11.7-24.1] ‡ NS 
Time between BL and last FU (years) 
(n) 
2.0 [1.0-2.5] (21) 2.0 [1.0-3.3] (45) 2.1 [1.0-2.6] (20) NS 
Time between BL and conversion 
(years) (n) 
1.1 [0.9-1.2] (5) 1.8 [1.0-2.1] (17) - NS 
MMSE from 0-30 28.7 [27.5-30.0] ^,# 25.7 [23.0-28.0] #,‡ 22.0 [20.3-24.0] ^,‡ 0.001 
YOE (years) (n) 16.8 [12.8-20.3] (24) # 15.1 [12.0-19.0] (43) 14.1 [12.0-16.0] (19) ‡ 0.018 
WB (%) -1.26 [-2.31 : -0.41] -1.62 [-2.66 : -0.81] -1.64 [-2.79 : -0.64] NS  
GM (%) -0.83 [-1.73 : -0.20] -1.26 [-2.78 : -0.46] -1.37 [-2.59 : -0.49] NS 
WM (%) -1.85 [-2.78 : -1.26] -2.14 [-3.52 : -0.49] -2.01 [-3.00 : -0.70] NS 
CSF (%) 4.66 [1.73 : 7.91] 4.78 [2.38 : 7.20] 4.09 [2.26 : 5.96] NS 
CGM (%) -0.88 [-1.82 : -0.19] -1.28 [-2.90 : -0.38] -1.42 [-2.64 : -0.27] NS 
WMH (mL) -0.31 [-0.99 : 1.37] -0.75 [-2.31 : 1.03] 2.22 [-0.05 : 2.22] NS 
Legend: data are mean and [IQR], percentages (%), and numbers (n). P-values are general ANCOVA test results, whereas the 
p-values described below are based on the differences of post hoc analyses. Changes in normalized brain volumes (WB, GM, 
WM, CSF, and CGM) at two time points are reported in percentages (%). WMH volume changes at two time points are 
reported in mL. 
¶ HC-SCD and MCI p=-0.006; HC-SCD and AD dementia p=0.009. ^ Significantly different compared to MCI. # Significantly 
different compared to AD dementia. ‡ Significantly different compared to HC-SCD.  
Abbreviations: AD Alzheimer’s disease; BL baseline; CGM cortical grey matter; HC-SCD group of controls and subjective 
cognitive decline; CSF cerebrospinal fluid; FU follow-up; GM grey matter; IQR interquartile range; MCI mild cognitive 
impairment; MMSE Mini-Mental State Examination; NS not significant; REMEMBER retrospective Belgian multi-center MRI 




Table 3 Diagnostic performance of volumetric measurements between cognitively healthy controls and AD dementia patients  
 Versus SCD stage  Versus MCI stage  Versus AD dementia stage 
 AUC Sens(%) Spec(%) 95% CI  AUC Sens(%) Spec(%) 95% CI  AUC Sens(%) Spec(%) 95% CI 
WB               
HC 0.700 81.1 52.6 0.626-0.775  0.820 84.4 67.4 0.774-0.865  0.882 85.6 78.8 0.847-0.918 
SCD       0.645 67.0 57.1 0.584-0.706  0.750 67.0 73.3 0.697-0.804 
               
GM               
HC  0.655 78.7 54.2 0.576-0.735  0.753 82.0 63.2 0.702-0.804  0.795 79.8 71.4 0.746-0.844 
SCD      0.613 63.5 57.5 0.552-0.674  0.674 86.5 47.1 0.614-0.735 
               
WM               
HC  0.629 78.7 44.8 0.549-0.709  0.703 78.7 52.4 0.643-0.764  0.746 78.7 59.9 0.688-0.805 
SCD       0.585 31.3 85.9 0.520-0.649  0.636 70.8 50.2 0.571-0.701 
               
CSF               
HC  0.706 58.4 77.1 0.631-0.780  0.783 597.5 67.4 0.732-0.834  0.824 85.4 70.9 0.776-0.872 
SCD       0.615 63.5 59.3 0.552-0.677  0.673 71.9 59.5 0.612-0.735 
               
CGM               
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HC  0.656 79.8 56.3 0.577-0.736  0.749 85.4 59.3 0.698-0.800  0.791 79.8 72.2 0.741-0.841 
SCD      0.607 79.2 39.8 0.545-0.669  0.664 85.4 47.6 0.603-0.726 
               
WMH               
HC 0.678 83.7 51.1 0.576-0.779  0.811 83.7 74.8 0.737-0.885  0.852 81.4 84.5 0.787-0.916 
SCD      0.628 62.1 63.4 0.545-0.711  0.684 48.5 84.5 0.604-0.764 
Legend: data are AUC, sensitivity, specificity, and 95% CI. AUCs were determined by ROC for all volumetric measurements. Highest accuracies were detected between HC and AD dementia 
(0.746-0.882) or MCI patients (0.703-0.820) and between SCD and AD dementia patient (0.629-0.706), with the highest accuracies for WB. However, differentiating in the earlier stages of the 
disease showed lower accuracies (HC vs. SCD 0.629-0.796; SCD vs. MCI 0.558-0.645) for all volumetric measurements. 
Abbreviations: AD Alzheimer’s disease; AUC area under the curve; CGM cortical grey matter; CI confidence interval; CSF cerebrospinal fluid; GM grey matter; HC cognitively healthy controls; MCI 




Table 4 Prediction of disease severity based on extracted MRI measures by the MMSE score 
 Model 1 - volume Model 2 – volume: age and clinical diagnosis at BL 
 R2 β [95% CI] p-value R2 β [95% CI] p-value 
WB (n=804) 0.165  0.406 [0.34 : 0.47] 0.001 0.422 0.150 [0.08 : 0.22] 0.001 
GM (n=746) 0.115 0.339 [0.27 : 0.41] 0.001 0.449 0.156 [0.10 : 0.21] 0.001 
WM (n=746) 0.047 0.216 [0.14 : 0.29] 0.001 0.428 0.012 [-0.05 : 0.07] 0.706 
CSF (n=746) 0.111 -0.333 [-0.40 : -0.26] 0.001 0.439 -0.119 [-0.18 : -0.06] 0.001 
CGM (n=746) 0.107 0.327 [0.26 : 0.40] 0.001 0.447 0.148 [0.09 : 0.21] 0.001 
WMH (n=459) 0.063 -0.252 [.034 : -0.16] 0.001 0.426 -0.044 [-0.12 : 0.04] 0.280 
Legend: data are R square (R2), standardized regression coefficients (β-values) with 95% confidence intervals [95% CI], and p-
values. Model 1 predicted the MMSE score significantly for all volumes, whereas model 2 showed a significant difference for 
WB, GM, CSF, and CGM when age and clinical diagnosis at baseline were introduced to the analysis. 
Abbreviations: BL baseline; CGM cortical grey matter; CI confidence interval; CSF cerebrospinal fluid; GM grey matter; MMSE 

















Figure 1 WB, GM, and CGM volumes across the different clinical diagnosis 
Scatterplots of WB (A), GM (B), and CGM (C) volumes in mL per clinical diagnostic category with their corresponding mean±SD. 
Significant differences were reported between clinical diagnoses, p=0.001* or p<0.05 (a-d). Volumes were significantly 
different between a clinical diagnostic group and cognitively healthy controls (a), to SCD (b), to MCI (c), or to AD dementia 
patients (d). WB was significantly different between all diagnostic groups. GM was significantly different between all 
diagnostic groups, except between controls and SCD. The CGM was significantly different between controls and SCD vs. MCI 
and AD dementia.  
Abbreviations: AD Alzheimer’s disease; CGM cortical grey matter; GM grey matter; MCI mild cognitive impairment; SCD 




Figure 2 WB, GM, and CGM volumes across slow and fast decliners in the total population based on 
MMSE 
Scatterplots of WB (A), GM (B), and CGM (C) volumes in mL at baseline with their corresponding mean ±SD. The MMSE slopes 
were calculated based on the difference in MMSE scores and were divided by the follow-up time. Subjects were categorized 
as slow decliners in case the MMSE slope was smaller than three, and if the slope was equal or larger than three a subject 
was categorized as a fast decliner. Significant differences were found for all volumes showed.  
 






Validation process of MSmetrix 
MSmetrix has been specifically designed to measure atrophy in patients with multiple sclerosis (MS) 
and has been validated in these patients [47-51]. Within this validation process test-retest scans were 
obtained in 18 MS patients, which were scanned on two Philips Healthcare systems (Philips, Best, The 
Netherlands) on the same day; 1.5Tesla (T, Intera) and 3T (Achieva) [48]. This study showed that 
MSmetrix was more robust compared to SIENA (FSL, http://www.fmrib.ox.ac.uk/fsl), as the median 
percentage error of WB volume measurements between 1.5T and 3T scanners was 0.35%, as compared 
to 2.99% for SIENA.  
Next, test-retest scans were obtained in 10 MS patients, which were scanned twice per scanner at 
three different scanners (General Electric (GE) Medical Systems Discovery MR750w, n=8; SIEMENS 
Skyra, n=8; Philips Medical Systems Achieva, n=7) [47]. This study demonstrated a small measurement 
error across the three 3T scanners with a median value of 0.13% (MSmetrix) and 0.17% (SIENA), which 
was not significantly different between the two different segmentation methods. The daily 
physiological processes were evaluated in three subjects scanned two times on 20 different days within 
a 31-day period, and a significantly smaller overall error for WB atrophy was detected when measures 
were analyzed by MSmetrix (0.19%) compared to SIENA (0.31%). In addition, no significant differences 
were observed between MSmetrix and SIENA with regard to the confidence interval (CI) of WB atrophy 
for 6-month intervals compared to the one year interval.  
The usage of T1 only versus T1 over FLAIR with MSmetrix was investigated in 33 MS patients. The 
difference between the two image protocols, and thus analyzing techniques, was 5.74mL (median) 
with a Pearson R of 1.00 (unpublished data).  
Moreover, studies have shown it is robust for different scanners without parameter tuning and 
provides accurate segmentations with a good reproducibility [49, 50]. The accuracy was evaluated by 
comparing the output from MSmetrix-cross with Lesion Segmentation Tool (LST) [68] and Lesion-
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Topology-preserving Anatomical Segmentation (TOADS) [69], two expert reference segmentations, in 
20 MS patients. In here, spatial overlap had a mean ±standard deviation (SD) of 0.67 ±0.11 and an 
interclass correlation coefficient equals 0.8, indicating a good volumetric agreement between 
MSmetrix and expert labelling [50]. Next, MSmetrix-long was evaluated by LST, and the median Dice 
score was 0.63 with a Pearson correlation coefficient equals to 0.96 [49]. Again a good agreement, and 
thus, MSmetrix-long is able to accurately and reproducibly measure new, enlarging, disappearing, 
shrinking, and static volumes in MS populations.  
When MSmetrix, FreeSurfer, SIENA, and Statistical Parametric Mapping (SPM) were compared, 
differences in atrophy measurements were larger compared to typical atrophy rates observed in MS, 
even at WB level [51]. MSmetrix-cross behaved similar to SPM and MSmetrix-long to SIENA, both in 
terms of mean volume difference as well as proportional error.  
In conclusion, MSmetrix is a robust method to analyze different MRI scans with different protocols 





Table 1 Overview of the REMEMBER study population based on quality control (QC) of obtained 
volumes by MSmetrix. 
  Controls SCD MCI AD dementia Total 
Center 1 45 43 139 96 323 
Center 2 
 
2 13 15 30 
Center 3 
 
34 48 14 96 
Center 4 
   
58 58 





2 100 77 179 
Center 7 21 
 






Total cohort 93 102 379 313 887 
  
    
  
Rejected after QC 3 5 39 36 83 
WB volumes - approved 90 97 340 277 804 
Approved with remarks  1 1 6 50 58 
GM, WM, CSF, CGM volumes - 
approved 89 96 334 227 746 
  
    
  
No FLAIR available 35 23 118 82 258 
Rejected after QC 15 13 59 83 170 
WMH - approved 43 66 202 148 459 
Legend: overview of the total REMEMBER cohort (eight centers), including cognitively healthy controls, SCD, MCI and AD 
dementia patients (n=887). Volumetric measurements were approved for all volumes (n=746) or MRI scans were completely 
(n=83) or partly rejected (n=58). Therefore, WB volumes could be analyzed in 804 subjects and the other volumes (GM, WM, 
CSF, CGM) in 746 subjects. For WMH a FLAIR sequence should be available (n=629) and approved by QC (n=459).  
Abbreviations: AD Alzheimer’s disease; CGM cortical grey matter; CSF cerebrospinal fluid; GM grey matter; MCI mild cognitive 
impairment; MRI magnetic resonance imaging; QC quality control; REMEMBER retrospective Belgian multi-center MRI 





Table 2 Detailed information of MRI scanner and image sequences. 
  HC (n=93) SCD (n=102) MCI (n=379) AD (n=313) Total (n=887) 
Scanner type       
 GE medical systems  21 [95.2] 64 [78.1] 55 [83.6] 140 [82.9] 
                     1.5T   16 [93.8] 37 [83.8] 37 [83.8] 90 [85.6] 
                     3.0T  5 [100.0] 27 [70.4] 18 [83.3] 50 [78.0] 
 Philips  27 [96.3] 52 [96.2] 142 [94.4] 87 [71.3] 308 [88.3] 
                     1.5T  22 [90.9] 62 [90.3] 35 [80.0] 119 [87.4] 
                     3.0T 27 [96.3] 30 [100.0] 80 [97.5] 52 [65.4] 189 [88.9] 
 SIEMENS 66 [95.5] 29 [89.7] 173 [86.7] 171 [69.6] 439 [81.5] 
                     1.5T  6 [83.3] 45 [73.3] 75 [41.3] 126 [54.8] 
                     3.0T 66 [95.5] 23 [91.3] 128 [91.4] 96 [91.7] 313 [92.3] 
       
Field strength       
 1.5T  44 [90.9] 144 [83.3] 147 [61.2] 335 [74.6] 
 3.0T 93 [95.7] 58 [96.6] 235 [91.1] 166 [82.5] 552 [89.9] 
       
Voxel size       
 3D T1 93 [95.7] 97 [95.9] 367 [90.7] 300 [74.3] 857 [86.1] 
 2D T1  5 [60.0] 12 [8.3] 13 [30.8] 30 [26.7] 
 Slice thickness ≤3mm 93 [95.7] 95 [97.9] 333 [95.2] 266 [78.6] 787 [90.0] 
 Slice thickness >3mm  7 [42.9] 46 [40.0] 47 [38.3] 100 [38.0] 
       
 3D FLAIR 45 [95.6] 23 [95.7] 85 [90.6] 58 [93.1] 211 [92.9] 
 2D FLAIR 13 [0.0] 56 [78.6] 176 [71.0] 173 [54.3] 418 [62.9] 
 Slice thickness ≤3mm  10 [100.0] 11 [90.9] 21 [81.0] 42 [88.1] 
 Slice thickness >3mm 58 [74.1] 69 [81.2] 250 [76.8] 210 [62.4] 587 [71.9] 
 Legend: data are numbers and between brackets the percentage (%) of subjects with approved volumetric measurements 
based on the visual QC. Information about the MRI scanner types, field strengths, and voxel sizes per clinical diagnostic group, 
including cognitively healthy controls, SCD, MCI and AD dementia patients (n=887).  
Scanner types were GE medical systems; 1.5T (Signa) or 3.0T (Discovery), Philips; 1.5T (Achieva, Interna) or 3.0T (Achieva, 
Ingenia), and SIEMENS; 1.5T (Aera, Avanto, Symphony) or 3.0T (Allegra, TrioTim, Skyra, Prisma). 
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The 3T scanners had more approved scans compared to the 1.5T scanners, in which less cognitive impairment showed a 
higher percentage of approved scans (HC>SCD>MCI>AD dementia). For the different scanner types, this phenomenon was 
also detected, as less cognitive impairment had a higher percentage of approved scans for both the Philips and SIEMENS 
scanners. This trend was found for GE scanners as well, however the MCI patients had a lower percentage of approved scans 
compared to the AD dementia patients.  
Smaller slice thickness (≤3mm) and 3D T1/FLAIR sequences had a higher percentage of approved scans compared to larger 
slice thickness (>3mm) and 2D T1/FLAIR sequences. Again, with a higher percentage of approved scans in less cognitive 
impaired subjects (HC>SCD>MCI>AD dementia). 
Abbreviations: AD Alzheimer’s disease; GE general electric; HC cognitively healthy controls; MCI mild cognitive impairment; 
MRI magnetic resonance imaging; QC quality control; REMEMBER retrospective Belgian multi-center MRI biomarker study in 






Table 3 Overview of analyzes based on T1 or T1 in combination with FLAIR. 
  Controls SCD MCI AD  Total 
T1 only  35 23 108 68 234 
 WB volumes - 
approved 
34 22 99 61 216 
 GM, WM, CSF, CGM 
volumes - approved 
33 22 96 60 211 
 %Rejected scans 2.8 4.3 8.3 10.3 7.7 
       
T1 and FLAIR  58 79 271 245 653 
 WB volumes - 
approved 
56 75 241 216 588 
 GM, WM, CSF, CGM 
volumes - approved 
56 74 238 167 535 
 %Rejected scans 3.4 5.1 11.1 11.8 9.9 
       
Total cohort  93 102 379 313 887 
Legend: overview of the distribution of image sequences (T1 or T1/FLAIR) per clinical diagnostic group, including cognitively 
healthy controls, SCD, MCI and AD dementia patients (n=887). Volumetric measurements based on only T1 (n=234) or T1 in 
combination with FLAIR (n=653). Clinical diagnostic groups were divided bases on the visual QC (see Table 1); approved, 
approved with remarks, and rejected. The percentage of rejected scans per clinical diagnosis, and also in the total cohort, 
were for both analyses (T1 only or T1 and FLAIR) comparable. No difference in the usage of T1 only versus T1 in combination 
with FLAIR was detected, as both analyzing methods had less than 10% rejected scans, respectively 7.7% and 9.9%. 
Abbreviations: AD Alzheimer’s disease; CGM cortical grey matter; CSF cerebrospinal fluid; GM grey matter; MCI mild cognitive 
impairment; MRI magnetic resonance imaging; QC quality control; REMEMBER retrospective Belgian multi-center MRI 





Table 4 Cut-off values of the volumetric measurements. 
  Cut-off (mL)   
  Versus SCD stage Versus MCI stage Versus AD dementia stage 
WB     
 HC 1390.0 1383.2 1379.9 
 SCD   1359.9 1359.7 
     
GM     
 HC 816.6 809.9 814.4 
 SCD   799.5 764.3 
     
WM     
 HC 563.2 563.9 563.9 
 SCD   605.5 550.4 
     
CSF     
 HC 531.9 597.5 600.8 
 SCD   617.1 637.2 
     
CGM     
 HC 770.6 760.1 769.9 
 SCD   733.7 723.9 
     
WMH     
 HC 5.9 5.8 5.4 
 SCD   8.0 5.4 
Legend: data are cut-off values (mL).  
Abbreviations: AD Alzheimer’s disease; CGM cortical grey matter; CSF cerebrospinal fluid; GM grey matter; HC cognitively 
healthy controls; MCI mild cognitive impairment; SCD subjective cognitive decline; WB whole brain; WM white matter; WMH 
white matter hyperintensities. 
 
